Please use this identifier to cite or link to this item:
Title: Influence of antipsychotics on metabolic syndrome risk in patients with schizophrenia
Authors: Korićanac A.
Tomic Lucic, Aleksandra
Veselinović M.
Bazic Sretenovic, Danijela
Bucic G.
Azanjac A.
Radmanovic O.
Matovic, Milovan
Stanojević M.
Jurisic Skevin, Aleksandra
Simovic Markovic, Bojana
Pantic, Jelena
Arsenijevic, Nebojsa
Radosavljevic, Gordana
Nikolic M.
Zornic, Nenad
Nesic, Jelena
Muric, Nemanja
Radmanovic, Branimir
Journal: Frontiers in Psychiatry
Issue Date: 25-Jul-2022
Abstract: Objective: Many studies so far have shown that antipsychotic therapy may have an effect on the development of metabolic syndrome in patients diagnosed with schizophrenia. Our goal was to determine whether our respondents are at risk for developing metabolic syndrome and who is more predisposed to it. Methods: In a stable phase, 60 patients diagnosed with schizophrenia were equally divided into three groups according to the drug (risperidone, clozapine, and aripiprazole monotherapy). Control group had 20 healthy examinees. Patients were evaluated first using The Positive and Negative Syndrome Scale (PANSS). Prolactin, lipid status, glycemia, insulin, cytokine values (IL-33, TGF-β, and TNF-α) and C-reactive protein (CRP) were measured. Also, Body mass index (BMI), Homeostatic Model Assesment for Insulin Resistance (HOMA index), waist and hip circumference (WHR) and blood pressure (TA) measurement were performed in the study. Results: Patients treated with risperidone compared to healthy control subjects and aripiprazol group of patients had statistically significant difference in prolactin levels. In clozapine group compared to healthy control group values of HDL cholesterol and glucose level were statistically significant different. In aripiprazole group compared to healthy control group value of BMI was statistically significant different. Statistically significant correlations were found in TNF-α with glucose and HOMA index in risperidone treated patients and with BMI in clozapine group of patients; IL-33 with glucose in risperidone and with BMI in clozapine group of patients and TGF-β with glucose in risperidone group, with insulin and HOMA index in clozapine group and statistically significant negative correlation with LDL cholesterol in aripiprazole group of patients. Conclusion: Patients on risperidone and clozapine therapy may be at greater risk of developing metabolic syndrome than patients treated with aripiprazole. Statistically significant difference in concentration of TNF-α and TGF-β was in the group of patients treated with risperidone compared to healthy control group.
Type: article
DOI: 10.3389/fpsyt.2022.925757
SCOPUS: 85136812569
Appears in Collections:Faculty of Medical Sciences, Kragujevac

Page views(s)




Files in This Item:
File Description SizeFormat 
10.3389-fpsyt.2022.925757.pdf335.45 kBAdobe PDFThumbnail

Items in SCIDAR are protected by copyright, with all rights reserved, unless otherwise indicated.